ArticleCell2021
Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers.
0numbers the graph read from it
0cells of the map it votes in
149citing papers in PubMed
11.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
149 citing papers in PubMed, 184 citations in OpenAlex.
- ILC3s as central regulators of mucosal homeostasis and disease pathogenesis (Review).International journal of molecular medicine · 2026Review
- Mucosal immunity: mechanism and application in cancer immunotherapy.Journal of hematology & oncology · 2026Review
- Microbiome-Immune Interactions as Determinants of Checkpoint Inhibitor Efficacy in Hepatocellular Carcinoma.International journal of molecular sciences · 2026Review
- Oral hydrogel systems in lower gastrointestinal disorders: From disease-based therapy to microbiota-guided design.Materials today. Bio · 2026Review
- IL-27 shapes NK cell heterogeneity and function in colorectal cancer.Journal for immunotherapy of cancer · 2026Article
- Targeting CD3L1-NRP2 disarms myeloid-driven tumor immune evasion.EMBO molecular medicine · 2026Article
- Immunotherapy resistance in colorectal cancer: therapeutic strategies and biomarker-guided approaches.Cancer cell international · 2026Review
- B7 costimulation antagonizes RORγt+ regulatory T cells and immune tolerance in the intestine.The Journal of experimental medicine · 2026Article
- Neuro-immune interactions in gastrointestinal oncology: Mechanisms, challenges, and therapeutic potential.Innovation (Cambridge (Mass.)) · 2026Review
- Review
- Intratumoral Microorganisms in Tumors: Current Understanding and Emerging Therapeutic Strategies.MedComm · 2026Review
- Review
- IDH1 Mutant Glioma Favors Group 3 Innate Lymphoid Cells and Is Resistant to Immune Checkpoint Expression.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Tumor-infiltrating immature innate lymphoid cells in colorectal cancer are biased toward ILC1/tissue-resident NK cell differentiation.Nature communications · 2026Article
- Reshaping the colorectal cancer immune microenvironment: insights from single-cell and spatial omics.Cancer cell international · 2026Review
- The conserved noncoding sequence CNS11 is a master control region forScience advances · 2026Article
- Tfam-mediated metabolic perturbation in RORγtCell reports · 2026Article
- RORγtNature communications · 2026Article
- Innate lymphoid cell heterogeneity and etiology-specific reprogramming in hepatocellular carcinoma.NPJ precision oncology · 2026Article
- Article
89 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
14 authors at 5 institutions in 3 countries.
Jeremy GocJill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, NY, USA; Joan and Sanford I. Weill Department of Medicine, Division of Gastroenterology and Hepatology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Department of Microbiology and Immunology, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Mengze LvJill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, NY, USA; Joan and Sanford I. Weill Department of Medicine, Division of Gastroenterology and Hepatology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Department of Microbiology and Immunology, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Nicholas J BessmanJill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, NY, USA; Joan and Sanford I. Weill Department of Medicine, Division of Gastroenterology and Hepatology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Department of Microbiology and Immunology, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Anne-Laure FlamarJill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, NY, USA; Joan and Sanford I. Weill Department of Medicine, Division of Gastroenterology and Hepatology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Department of Microbiology and Immunology, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Sheena SahotaJill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, NY, USA; Joan and Sanford I. Weill Department of Medicine, Division of Gastroenterology and Hepatology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Department of Microbiology and Immunology, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Hiroaki SuzukiJill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, NY, USA; Joan and Sanford I. Weill Department of Medicine, Division of Gastroenterology and Hepatology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Department of Microbiology and Immunology, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Fei TengJill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, NY, USA; Joan and Sanford I. Weill Department of Medicine, Division of Gastroenterology and Hepatology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Department of Microbiology and Immunology, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Gregory G PutzelJill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, NY, USA.
JRI Live Cell BankJill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Gerard EberlMicroenvironment and Immunity Unit, Institut Pasteur, Paris, France.
David R WithersCollege of Medical and Dental Sciences, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Janelle C ArthurCenter for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Manish A ShahDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA; Gastrointestinal Oncology Program, Center for Advanced Digestive Care, Sandra and Edward Meyer Cancer Center, New York-Presbyterian Hospital, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Gregory F SonnenbergJill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, NY, USA; Joan and Sanford I. Weill Department of Medicine, Division of Gastroenterology and Hepatology, Weill Cornell Medicine, Cornell University, New York, NY, USA; Department of Microbiology and Immunology, Weill Cornell Medicine, Cornell University, New York, NY, USA. Electronic address: gfsonnenberg@med.cornell.edu.
Cornell University · USInstitut Pasteur · FRNewYork–Presbyterian Hospital · USUniversity of Birmingham · GBUniversity of North Carolina at Chapel Hill · US
Funding
Regulation of protective immunity following enteric viral infectionU01AI095608 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI ARTIS, DAVID, SONNENBERG, GREGORY F · 2011 to 2025
$11.0MInterleukin-2 regulation of mucosal inflammationR01AI145989 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI SONNENBERG, GREGORY F · 2019 to 2025
$5.3MImmune regulation of intestinal health and diseaseR01AI123368 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Gregory F Sonnenberg · 2016 to 2026
$3.6MNeuro-immune regulation of intestinal inflammationR01DK126871 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI ARTIS, DAVID · 2020 to 2024
$3.2MInnate immune regulation of neuroinflammationR01AI162936 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI SONNENBERG, GREGORY F · 2021 to 2025
$3.1MDefining a novel mechanism of mucosal healingR01AI143842 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI SONNENBERG, GREGORY F · 2019 to 2023
$2.5MImmune regulation of tissue iron in health and diseaseDP2AI154440 · NIAID · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI BESSMAN, NICHOLAS J. · 2021 to 2025
$2.3MMicrobiota-mediated fibrotic remodeling in the inflamed intestineR01DK124617 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ARTHUR, JANELLE C · 2020 to 2024
$1.9MThe role of local iron homeostasis in inflammatory bowel diseaseK01DK128308 · NIDDK · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI BESSMAN, NICHOLAS J. · 2021 to 2025
$883kIntestinal inflammation and genotoxicity of the colonic-adherent microbiotaK01DK103952 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ARTHUR, JANELLE C · 2014 to 2018
$758kDefining host-microbiota interactions during colorectal cancer and immune checkpoint blockadeR21CA249274 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI SONNENBERG, GREGORY F · 2020 to 2021
$436kThe molecular basis of host-microbiota interactionsF32AI124517 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI BESSMAN, NICHOLAS J. · 2017 to 2020
$193kNCI NIH HHS R21 CA249274NIAID NIH HHS DP2 AI154440NIAID NIH HHS F32 AI124517NIAID NIH HHS R01 AI123368NIAID NIH HHS R01 AI143842NIAID NIH HHS R01 AI145989NIAID NIH HHS R01 AI162936NIAID NIH HHS U01 AI095608NIDDK NIH HHS K01 DK103952NIDDK NIH HHS K01 DK128308NIDDK NIH HHS R01 DK124617NIDDK NIH HHS R01 DK126871Wellcome Trust 110199/Z/15/Z
Abstract
Group 3 innate lymphoid cells (ILC3s) regulate immunity and inflammation, yet their role in cancer remains elusive. Here, we identify that colorectal cancer (CRC) manifests with altered ILC3s that are characterized by reduced frequencies, increased plasticity, and an imbalance with T cells. We evaluated the consequences of these changes in mice and determined that a dialog between ILC3s and T cells via major histocompatibility complex class II (MHCII) is necessary to support colonization with microbiota that subsequently induce type-1 immunity in the intestine and tumor microenvironment. As a result, mice lacking ILC3-specific MHCII develop invasive CRC and resistance to anti-PD-1 immunotherapy. Finally, humans with dysregulated intestinal ILC3s harbor microbiota that fail to induce type-1 immunity and immunotherapy responsiveness when transferred to mice. Collectively, these data define a protective role for ILC3s in cancer and indicate that their inherent disruption in CRC drives dysfunctional adaptive immunity, tumor progression, and immunotherapy resistance.
Indexed as
Disease ProgressionImmunity, InnateImmunotherapyAnimalsCell CommunicationCell PlasticityColonic NeoplasmsFecesHistocompatibility Antigens Class IIHumansImmune Checkpoint InhibitorsInflammationInflammatory Bowel DiseasesIntestinesLymphocytesMiceHistocompatibility Antigens Class IIImmune Checkpoint Inhibitorscheckpoint blockade immunotherapycolorectal cancerinnate lymphoid cellsintestinal inflammationmicrobiota
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.